KU60019 inhibits ovarian cancer progression by targeting DGAT1/has-miR-1273g-3p axis
PLOS One · 2025
DOI: 10.1371/journal.pone.0325213 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Zhanchuan Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Lequn Branch, The First Hospital of Jilin University, Changchun, Jilin, China. Hauptthemen laut MEDLINE: MicroRNAs, Ovarian Neoplasms, Diacylglycerol O-Acyltransferase, Morpholines. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the development fund of Lequn Branch, The First Hospital of Jilin University.
Abstract (Originalsprache)
Ataxia telangiectasia mutated (ATM) blockage can induce apoptosis in ovarian cancer. However, the molecular mechanisms underlying this process remain poorly understood. In this study, ovarian cancer cells (SKOV3) were treated with an ATM inhibitor (KU60019) for 24 hours, and the fold changes of DGAT1 and hsa-miR-1273g-3p were quantified by real-time quantitative polymerase chain reaction (RT-qPCR). Gene Ontology (GO) and pathway enrichment analyses of DGAT1-associated functions were performed. Hsa-miR-1273g-3p mimics were used to investigate the relationship between DGAT1 and hsa-miR-1273g-3p in ovarian cancer cells under ATM inhibitor treatment, and cell apoptosis rate, viability, and migration were detected. The DGAT1 inhibitor reversed KU60019-induced migration impairment in SKOV3 cells. Finally, Kaplan-Meier analysis showed the correlation between DGAT1 level and survival in ovarian cancer patients. We found that ATM blockage significantly suppressed hsa-miR-1273g-3p level and elevated DGAT1 level in SKOV3 cells. DGAT1 was enriched in cytokine receptor interaction, T cell receptor signaling pathway, and cell apoptosis. Hsa-miR-1273g-3p mimics reversed suppression of DGAT1 and impaired cell viability induced by KU60019. Higher levels of DGAT1 associated with worse survival in ovarian cancer patients. KU60019 induced ovarian cancer cell impairment by enhancing DGAT1 level and suppressing hsa-miR-1273g-3p level. Our results demonstrate the antitumor effect of KU60019 in ovarian cancer depended on miR1273g-3p/DGAT1 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Lequn Branch, The First Hospital of Jilin University, Changchun, Jilin, China.
- Department of Cardiology, Lequn Branch, The First Hospital of Jilin University, Changchun, Jilin, China.
ORCID-Profile: Guodong Wu
Förderung
- the development fund of Lequn Branch, The First Hospital of Jilin University
Zitieren
APA
Ma, Z., Dang, R., & Wu, G. (2025). KU60019 inhibits ovarian cancer progression by targeting DGAT1/has-miR-1273g-3p axis. PLOS One. https://doi.org/10.1371/journal.pone.0325213
Vancouver
Ma Z, Dang R, Wu G. KU60019 inhibits ovarian cancer progression by targeting DGAT1/has-miR-1273g-3p axis. PLOS One. 2025. doi:10.1371/journal.pone.0325213
BibTeX
@article{Ma2025,
author = {Ma, Zhanchuan and Dang, Rongjing and Wu, Guodong},
title = {KU60019 inhibits ovarian cancer progression by targeting DGAT1/has-miR-1273g-3p axis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325213}
}
EUVIMED